Beyond Evidence: the counter-drone and software shift behind Axon's new money
Axon's core evidence software still anchors the business, but a growing share of revenue now comes from newer products, with counter-drone among the fastest-growing. Here is where that new money comes from and what would confirm the shift.
The short read
Axon's new money is coming from products built on top of its core platform, not from the core alone. More than one-third of its software revenue now comes from offerings beyond Axon Evidence. That includes real-time operations, Records, the AI Era Plan, counter-drone software and Axon 911.1
The fastest line is counter-drone. Platform solutions revenue grew 123% to $150 million, and management said Dedrone drove much of that.2 For investors, the question has moved on from whether the core holds. It is now how far these newer lines can grow the revenue base without weakening the foundation underneath them.
In our data, $AXON leads the defense names we score. Leonardo DRS is second and Boeing is third. Each is finding new money in its own way.
The foundation stays put while the mix moves
Management still calls Axon Evidence the backbone of the software business. It describes it as the secure data foundation for the company's wider plans.4 That matters for the mix-shift story. The newer products are not separate bets. They sit on the same data layer agencies already use.
This is how a platform company usually broadens revenue. It first wins the system of record, here the evidence and data store. Then it sells the tools that run on that data: records software, real-time operations, 911 and AI features.1 Every added product makes the whole package harder to replace.
Management ties this directly to pricing. Axon says network effects and ecosystem integration are driving strong pricing power.5 Put simply, every new module that plugs into Evidence gives the company more to charge for when contracts renew.
Counter-drone: a new market inside a familiar customer base
The 123% growth in platform solutions, to $150 million, is the clearest sign of a new market opening up. Dedrone carried much of that growth.2 Counter-drone software appears on the company's own list of offerings beyond Evidence.1 So this is new revenue sold through Axon's existing software relationships.
Smaller companies are in the space too. ParaZero Technologies, for example, is a micro-cap maker of drone parachutes and counter-drone products.6 The comparison matters for positioning. A counter-drone tool sold by a vendor that already holds an agency's evidence and operations data starts with a different kind of access.
The risk sits in the same number. When one acquired product drives much of a segment's growth, the segment's growth rate depends on that one product.2 Watch whether the newer lines broaden out, so the growth no longer leans so heavily on one driver.
Conversions and new devices widen the funnel
Some of the new money comes from winning business that today belongs to other vendors. Axon says a significant number of agencies want to switch from their current license plate readers to Axon's. It credits the controls and privacy work it has done in that area.7 That is market-share growth in an existing category, driven by trust features rather than price.
Hardware still pulls its weight. Management called TASER 10 a standout in the quarter.8 It also pointed to interest in the Axon Body Mini, with trials starting to gain momentum.9 Trials come before contracts, so the Body Mini is an early signal rather than a revenue line yet.
Each new device matters because it feeds data into the platform. A new camera or reader sends more data into Evidence, and more data makes the software around it more useful.4 Hardware and software growth reinforce each other here.
How Leonardo DRS and Boeing find their new money
Leonardo DRS, second in our data, is growing by adding production capacity. The company is a qualified supplier on THAAD platforms and is adding capacity to support higher production.3 It is also adding capacity for tactical radar and revitalizing its foundry to make next-generation infrared sensors.10 Its new money depends on factory output keeping pace with programs it already supplies.
Boeing, third in our data, has a large order book behind it. Boeing Defense, Space & Security reported a record backlog of $101 billion.11 Commercial Airplanes' backlog rose to $612 billion.12 Boeing Global Services posted an 18.3% operating margin.13 Backlog shows revenue already ordered, and services show where margin is earned.
Side by side, the three show different sources of new money. Axon adds products on its own platform. DRS adds capacity behind existing programs. Boeing works through a deep backlog. Axon's version is the one most tied to selling new products to customers it already has.
What to watch next
The first marker is the software mix. More than one-third now comes from beyond Evidence.1 If that share keeps rising while Evidence stays the foundation, it confirms the platform model is working.4
The second is breadth inside platform solutions. Growth of 123% to $150 million is a strong figure.2 Next is whether real-time operations, Records and Axon 911 add enough that the line no longer leans so heavily on Dedrone.1
The third is conversion from interest to contracts. That means license plate reader switches7 and Body Mini trials9 turning into reported revenue. Each would show the company finding new money in categories where it is still the challenger.
What would change our view
- Platform solutions growth slows sharply without a second driver alongside Dedrone.2
- The share of software revenue from beyond Evidence stops rising, or falls.1
- License plate reader conversions or Body Mini trials fail to turn into contracts.7,9
- Management stops pointing to pricing power from network effects and ecosystem integration.5
If you buy for an agency, do you add tools like counter-drone, real-time operations or Axon 911 as part of an existing Evidence contract, or as separate purchases with their own budget?
Answer on XSources
- 1Earnings call AXON FY2026 Q2, transcript, Aug 5, 2026.
- 2Earnings call AXON FY2026 Q2, transcript, Aug 5, 2026.
- 3Earnings call DRS FY2026 Q2, transcript, Jul 30, 2026.
- 4Earnings call AXON FY2026 Q2, transcript, Aug 5, 2026.
- 5Earnings call AXON FY2026 Q2, transcript, Aug 5, 2026.
- 6Industry research note, research note, Oct 4, 2026.
- 7Earnings call AXON FY2026 Q2, transcript, Aug 5, 2026.
- 8Earnings call AXON FY2026 Q2, transcript, Aug 5, 2026.
- 9Earnings call AXON FY2026 Q2, transcript, Aug 5, 2026.
- 10Earnings call DRS FY2026 Q2, transcript, Jul 30, 2026.
- 11Earnings call BA FY2026 Q3, transcript, Oct 27, 2026.
- 12Earnings call BA FY2026 Q3, transcript, Oct 27, 2026.
- 13Earnings call BA FY2026 Q3, transcript, Oct 27, 2026.
For information only. Not investment advice.
Related research
All research →
Welding is getting busier: what the latest calls say about process tooling
The latest reports from welding and dispensing suppliers show volume and orders starting to do more of the work than price. Here is what Lincoln Electric, Graco, ITW and Nordson said, and what to watch next.
Liquid biopsy's quiet bottleneck: who is building lab capacity first
Three diagnostics companies used their latest earnings calls to talk about labs, automation and cost per test. In this corner of health care, capacity may matter as much as demand.
The closed-weight AI race: where Anthropic is gaining and OpenAI is defending
October's industry notes put the competition among closed-weight labs in sharper focus. Anthropic leads in coding, OpenAI is defending on trust and value, and smaller labs are pushing into decision models.